Top

Osteoporosis International

Published in:

01-04-2010 | Original Article

Bone turnover in patients with endogenous Cushing’s syndrome before and after successful treatment

Authors: Á. Szappanos, J. Tőke, D. Lippai, A. Patócs, P. Igaz, N. Szücs, L. Fütő, E. Gláz, K. Rácz, M. Tóth

Published in: Osteoporosis International | Issue 4/2010

Abstract

Summary

We investigated bone turnover and its restoration in a large number of patients in the active phase and after cure of endogenous Cushing’s syndrome. Furthermore, the usefulness of serum osteocalcin and collagen breakdown products as potential markers of active Cushing’s syndrome was also evaluated.

Introduction

Suppressed bone formation is one of the most characteristic features of Cushing’s syndrome (CS). Despite numerous previous reports, many aspects of the disturbed bone metabolism of these patients are unexplored. In this study, we investigated the time course of bone marker changes after the cure of CS as well as correlations between bone markers and serum cortisol concentrations.

Methods

Eighty-seven patients with CS were studied. Patients were followed up to 48 months after surgical cure. Serum osteocalcin (OC) and collagen breakdown products (CTX) were measured with immunochemiluminescence method and compared to the results of 161 healthy controls.

Results

OC showed a negative, while CTX displayed a positive correlation with serum cortisol. Patients with diabetes mellitus and myopathy had significantly lower serum OC levels compared to those without these complications. The area under the curve of OC obtained by receiver-operating characteristics analysis for the discrimination of patients with CS from healthy controls was 0.9227. Postoperative OC increased rapidly from the first few days or weeks reaching its maximum at the sixth month and remained stable after the 24th postoperative month.

Conclusions

Our study demonstrated significant correlations between serum cortisol and both bone formation and resorption markers in the active phase of CS. We propose that OC may serve as a sensitive biologic marker of glucocorticoid activity in endogenous CS during its active phase and it may reflect the clinical cure of the disease.

Mancini T, Doga M, Mazziotti G et al (2004) Cushing’s syndrome and bone. Pituitary 7:249–252CrossRefPubMed

Vestergaard P, Lindholm J, Jørgensen JO et al (2002) Increased risk of osteoporotic fractures in patients with Cushing’s syndrome. Eur J Endocrinol 146:51–56CrossRefPubMed

Piovesan A, Terzolo M, Reimondo G et al (1994) Biochemical markers of bone and collagen turnover in acromegaly or Cushing’s syndrome. Horm Metab Res 26:234–237CrossRefPubMed

Di Somma C, Pivonello R, Loche S et al (2002) Severe impairment of bone mass and turnover in Cushing’s disease: comparison between childhood-onset and adulthood-onset disease. Clin Endocrinol 56:153–158CrossRef

Francucci CM, Pantanetti P, Garrapa GG et al (2002) Bone metabolism and mass in women with Cushing’s syndrome and adrenal incidentaloma. Clin Endocrinol 57:587–593CrossRef

Cortet B, Cortet C, Blanckaert F et al (2001) Quantitative ultrasound of bone and markers of bone turnover in Cushing’s syndrome. Osteoporos Int 12:117–123CrossRefPubMed

Sartorio A, Ambrosi B, Colombo P et al (1988) Osteocalcin levels in Cushing’s disease before and after treatment. Horm Metab Res 20:70CrossRefPubMed

Hermus AR, Smals AG, Swinkels LM et al (1995) Bone mineral density and bone turnover before and after surgical cure of Cushing’s syndrome. J Clin Endocrinol Metab 80:2859–2865CrossRefPubMed

Kristo C, Godang K, Ueland T et al (2002) Raised serum levels of interleukin-8 and interleukin-18 in relation to bone metabolism in endogenous Cushing’s syndrome. Eur J Endocrinol 146:389–395CrossRefPubMed

10.

Kristo C, Jemtland R, Ueland T et al (2006) Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing’s syndrome: a prospective, long-term study. Eur J Endocrinol 154:109–118CrossRefPubMed

11.

Osella G, Terzolo M, Reimondo G et al (1997) Serum markers of bone and collagen turnover in patients with Cushing’s syndrome and in subjects with adrenal incidentalomas. J Clin Endocrinol Metab 82:3303–3307CrossRefPubMed

12.

Tauchmanovà L, Pivonello R, Di Somma C et al (2006) Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab 91:1779–1784CrossRefPubMed

13.

Chiodini I, Carnevale V, Torlontano M et al (1998) Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing’s syndrome. J Clin Endocrinol Metab 83:1863–1867CrossRefPubMed

14.

Godang K, Ueland T, Bollerslev J (1999) Decreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing’s syndrome. Eur J Endocrinol 141:126–131CrossRefPubMed

15.

Chiodini I, Torlontano M, Carnevale V et al (2008) Skeletal involvement in adult patients with endogenous hypercortisolism. J Endocrinol Invest 31:267–276PubMed

16.

Di Somma C, Pivonello R, Loche S et al (2003) Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing’s disease: a prospective study. Clin Endocrinol 58:302–308CrossRef

17.

Scommegna S, Greening JP, Storr HL et al (2005) Bone mineral density at diagnosis and following successful treatment of pediatric Cushing’s disease. J Endocrinol Invest 28:231–235PubMed

18.

Leong GM, Abad V, Charmandari E et al (2007) Effects of child- and adolescent-onset endogenous Cushing syndrome on bone mass, body composition, and growth: a 7-year prospective study into young adulthood. J Bone Miner Res 22:110–118CrossRefPubMed

19.

Füto L, Toke J, Patócs A et al (2008) Skeletal differences in bone mineral area and content before and after cure of endogenous Cushing’s syndrome. Osteoporos Int 19:941–949CrossRefPubMed

20.

Minetto M, Reimondo G, Osella G et al (2004) Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing’s syndrome. Osteoporos Int 15:855–861CrossRefPubMed

21.

Karavitaki N, Ioannidis G, Giannakopoulos F et al (2004) Evaluation of bone mineral density of the peripheral skeleton in pre- and postmenopausal women with newly diagnosed endogenous Cushing’s syndrome. Clin Endocrinol 60:264–270CrossRef

22.

Ohmori N, Nomura K, Ohmori K et al (2003) Osteoporosis is more prevalent in adrenal than in pituitary Cushing’s syndrome. Endocr J 50:1–7CrossRefPubMed

23.

Cooper MS, Syddall HE, Fall CH et al (2005) Circulating cortisone levels are associated with biochemical markers of bone formation and lumbar spine BMD: the Hertfordshire Cohort Study. Clin Endocrinol 62:692–697CrossRef

24.

van Schoor NM, Dennison E, Lips P et al (2007) Serum fasting cortisol in relation to bone, and the role of genetic variations in the glucocorticoid receptor. Clin Endocrinol (Oxf) 67:871–878CrossRef

25.

Majnik J, Szücs N, Patócs A et al (2004) Effect of single doses of dexamethasone and adrenocorticotrop hormone on serum bone markers in healthy subjects and in patients with adrenal incidentalomas and Cushing’s syndrome. J Endocrinol Invest 27:747–753PubMed

26.

Nieman LK, Biller BM, Findling JW et al (2008) The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:1526–1540CrossRefPubMed

27.

Elamin MB, Murad MH, Mullan R et al (2008) Accuracy of diagnostic tests for Cushing’s syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab 93:1553–1562CrossRefPubMed

Title: Bone turnover in patients with endogenous Cushing’s syndrome before and after successful treatment
Authors: Á. Szappanos
J. Tőke
D. Lippai
A. Patócs
P. Igaz
N. Szücs
L. Fütő
E. Gláz
K. Rácz
M. Tóth
Publication date: 01-04-2010
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 4/2010
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-009-0978-y

At a glance: The STEP trials

Springer Medicine

Bone turnover in patients with endogenous Cushing’s syndrome before and after successful treatment

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2010

Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies

Self-reported preclinical mobility limitation and fall history as predictors of future falls in older women: prospective cohort study

Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX™

The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK

Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk

Age- and gender-dependent changes in three-dimensional microstructure of cortical and trabecular bone at the human femoral neck